Omecamtiv mecarbil

Cardiac myosin activator CAS# 873697-71-3

Omecamtiv mecarbil

Catalog No. BCC3710----Order now to get a substantial discount!

Product Name & Size Price Stock
Omecamtiv mecarbil: 5mg $138 In Stock
Omecamtiv mecarbil: 10mg Please Inquire In Stock
Omecamtiv mecarbil: 20mg Please Inquire Please Inquire
Omecamtiv mecarbil: 50mg Please Inquire Please Inquire
Omecamtiv mecarbil: 100mg Please Inquire Please Inquire
Omecamtiv mecarbil: 200mg Please Inquire Please Inquire
Omecamtiv mecarbil: 500mg Please Inquire Please Inquire
Omecamtiv mecarbil: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of Omecamtiv mecarbil

Number of papers citing our products

Chemical structure

Omecamtiv mecarbil

3D structure

Chemical Properties of Omecamtiv mecarbil

Cas No. 873697-71-3 SDF Download SDF
PubChem ID 11689883 Appearance Powder
Formula C20H24FN5O3 M.Wt 401.43
Type of Compound N/A Storage Desiccate at -20°C
Synonyms CK-1827452
Solubility DMSO : 50 mg/mL (124.55 mM; Need ultrasonic)
Chemical Name methyl 4-[[2-fluoro-3-[(6-methylpyridin-3-yl)carbamoylamino]phenyl]methyl]piperazine-1-carboxylate
SMILES CC1=NC=C(C=C1)NC(=O)NC2=CC=CC(=C2F)CN3CCN(CC3)C(=O)OC
Standard InChIKey RFUBTTPMWSKEIW-UHFFFAOYSA-N
Standard InChI InChI=1S/C20H24FN5O3/c1-14-6-7-16(12-22-14)23-19(27)24-17-5-3-4-15(18(17)21)13-25-8-10-26(11-9-25)20(28)29-2/h3-7,12H,8-11,13H2,1-2H3,(H2,23,24,27)
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of Omecamtiv mecarbil

DescriptionOmecamtiv mecarbil (CK-1827452) is a specific activator of cardiac myosin activator and a clinical drug for left ventricular systolic heart failure.
TargetsATPase    

Omecamtiv mecarbil Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Omecamtiv mecarbil Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Omecamtiv mecarbil

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.4911 mL 12.4555 mL 24.9109 mL 49.8219 mL 62.2774 mL
5 mM 0.4982 mL 2.4911 mL 4.9822 mL 9.9644 mL 12.4555 mL
10 mM 0.2491 mL 1.2455 mL 2.4911 mL 4.9822 mL 6.2277 mL
50 mM 0.0498 mL 0.2491 mL 0.4982 mL 0.9964 mL 1.2455 mL
100 mM 0.0249 mL 0.1246 mL 0.2491 mL 0.4982 mL 0.6228 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on Omecamtiv mecarbil

Omecamtiv mecarbil (CK-1827452) is the first potent cardiac myosin activator that can specifically activate the cardiac myosin S1 domain but not other muscle myosins. In clinical trials, omecamtiv mecarbil has been considered as a promising therapeutic approach to treat systolic heart failure1.

Omecamtiv mecarbil accelerates the actin-dependent Pi release from cardiac myosin S1 domain, thus increases the rate of transition from weakly actin-bound state to strongly actin-bound state (EC50= 2.3 μM)1.

At the concentration of 200nM, omecamtiv mecarbil was reported to remarkably increase the contractility of adult rat cardiac myocytes without influencing calcium transient. In vivo, Omecamtiv mecarbil has been shown to improve cardiac function without changing myocardial oxygen consumption in both beagle dogs and Sprague-Dawley rats under isoflurane anesthesia1.

References:
1. Malik FI1, Hartman JJ, Elias KA, Morgan BP, Rodriguez H, Brejc K, Anderson RL, Sueoka SH, Lee KH, Finer JT, Sakowicz R, Baliga R, Cox DR, Garard M,Godinez G, Kawas R, Kraynack E, Lenzi D, Lu PP, Muci A, Niu C, Qian X, Pierce DW, Pokrovskii M, Suehiro I, Sylvester S, Tochimoto T, Valdez C, Wang W,Katori T, Kass DA, Shen YT, Vatner SF, Morgans DJ. Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. Science. 2011 Mar 18;331(6023):1439-43.

Featured Products
New Products
 

References on Omecamtiv mecarbil

Dose-dependent electrophysiological effects of the myosin activator omecamtiv mecarbil in canine ventricular cardiomyocytes.[Pubmed:27779469]

J Physiol Pharmacol. 2016 Aug;67(4):483-489.

Omecamtiv mecarbil (OM) is a myosin activator agent recently developed for treatment of heart failure. Although its action on extending systolic ejection time and increasing left ventricular ejection fraction is well documented, no data is available regarding its possible side-effects on cardiac ion channels. Therefore, the present study was designed to investigate the effects of OM on action potential morphology and the underlying ion currents in isolated canine ventricular myocytes using sharp microelectrodes, conventional patch clamp, and action potential voltage clamp techniques. OM displayed a concentration-dependent action on action potential configuration: 1 muM OM had no effect, while action potential duration and phase-1 repolarization were reduced and the plateau potential was depressed progressively at higher concentrations (10 - 100 muM; P < 0.05 compared to control). Accordingly, OM (10 muM) decreased the density of the transient outward K(+) current (Ito), the L-type Ca(2+) current (ICa) and the rapid delayed rectifier K(+) current (IKr), but failed to modify the inward rectifier K(+) current (IK1). It is concluded, that although the therapeutic concentrations of OM are not likely to influence cardiac ion currents significantly, alterations of the major cardiac ion currents can be anticipated at concentrations above those clinically tolerated.

Omecamtiv Mecarbil Enhances the Duty Ratio of Human beta-Cardiac Myosin Resulting in Increased Calcium Sensitivity and Slowed Force Development in Cardiac Muscle.[Pubmed:28082673]

J Biol Chem. 2017 Mar 3;292(9):3768-3778.

The small molecule drug Omecamtiv mecarbil (OM) specifically targets cardiac muscle myosin and is known to enhance cardiac muscle performance, yet its impact on human cardiac myosin motor function is unclear. We expressed and purified human beta-cardiac myosin subfragment 1 (M2beta-S1) containing a C-terminal Avi tag. We demonstrate that the maximum actin-activated ATPase activity of M2beta-S1 is slowed more than 4-fold in the presence of OM, whereas the actin concentration required for half-maximal ATPase was reduced dramatically (30-fold). We find OM does not change the overall actin affinity. Transient kinetic experiments suggest that there are two kinetic pathways in the presence of OM. The dominant pathway results in a slow transition between actomyosin.ADP states and increases the time myosin is strongly bound to actin. However, OM also traps a population of myosin heads in a weak actin affinity state with slow product release. We demonstrate that OM can reduce the actin sliding velocity more than 100-fold in the in vitro motility assay. The ionic strength dependence of in vitro motility suggests the inhibition may be at least partially due to drag forces from weakly attached myosin heads. OM causes an increase in duty ratio examined in the motility assay. Experiments with permeabilized human myocardium demonstrate that OM increases calcium sensitivity and slows force development (ktr) in a concentration-dependent manner, whereas the maximally activated force is unchanged. We propose that OM increases the myosin duty ratio, which results in enhanced calcium sensitivity but slower force development in human myocardium.

Direct Myosin Activation by Omecamtiv Mecarbil for Heart Failure with Reduced Ejection Fraction.[Pubmed:28315072]

Handb Exp Pharmacol. 2017;243:465-490.

Myosin is the indispensable molecular motor that utilizes chemical energy to produce force for contraction within the cardiac myocyte. Myosin activity is gated by intracellular calcium levels which are regulated by multiple upstream signaling cascades that can be altered for clinical utility using inotropic medications. In contrast to clinically available cardiac inotropes, Omecamtiv mecarbil is a novel direct myosin activator developed to augment left ventricular systolic function without the undesirable secondary effects of altered calcium homeostasis. Its identification and synthesis followed high-throughput screening of a reconstituted sarcomere, deliberate optimization, exquisite biochemical evaluation, and subsequently promising effects in animal models were demonstrated. Physiologically, it prolonged the duration of left ventricular systole in animal models, healthy adults, and patients with heart failure with reduced ejection fraction (HFrEF) without changing the velocity of pressure development, as assessed in animal models. It has been formulated for both intravenous and oral administration, and in both acute and chronic settings produced similar alterations in the duration of systole associated with beneficial increases in cardiac output, improvements in left ventricular volumes, and reductions in heart rate and often of natriuretic peptides. Small, asymptomatic increases in troponin were also observed in the absence of clinically evident ischemia. Clinically, the question remains as to whether the possible harm of this minimal troponin release is outweighed by the potential benefits of reduced neurohormonal activation, increased stroke volume and cardiac output, and improved ventricular remodeling in patients treated with Omecamtiv mecarbil. The resolution of this question is being addressed by a phase III outcomes trial of this potential novel therapy for heart failure.

Description

Omecamtiv mecarbil is a selective cardiac myosin activator.

Keywords:

Omecamtiv mecarbil,873697-71-3,CK-1827452,Natural Products,ATPase, buy Omecamtiv mecarbil , Omecamtiv mecarbil supplier , purchase Omecamtiv mecarbil , Omecamtiv mecarbil cost , Omecamtiv mecarbil manufacturer , order Omecamtiv mecarbil , high purity Omecamtiv mecarbil

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: